Dr. Matthew Davids is Director of the CLL Center an attending physician in the Lymphoma Program, Division of Hematologic Malignancies at Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. After obtaining an AB in chemistry at Harvard College, he completed his MD at Yale University School of Medicine. He served as an intern, resident, and assistant chief resident in internal medicine at New York-Presbyterian Weill Cornell Medical Center and Memorial Sloan-Kettering Cancer Center in New York City. He then completed his fellowship in hematology and oncology in Dana-Farber/Partners CancerCare, and a master’s degree in Medical Science (MMSc) at Harvard Medical School. Dr. Davids has an active translational research program in chronic lymphocytic leukemia (CLL), studying Bcl-2 biology in his laboratory and leading clinical trials to evaluate novel therapeutic strategies in patients with CLL and other hematologic malignancies. Much of his work has focused on the clinical development of the Bcl-2 inhibitor venetoclax and utilizing checkpoint blockade to enhance anti-tumor immunity in patients with hematologic malignancies who relapse post allogeneic hematopoietic cell transplantation.